S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Iambic Therapeutics Shares Drop 11% After Wider Quarterly Loss

Iambic Therapeutics shares fell 11% to $11.60 on Monday after the company reported a wider third-quarter loss and collaboration revenue below analysts’ expectations. The life-sciences and technology company made its public debut last month, selling nearly 9.38 million shares at $16 apiece.

Iambic Therapeutics Shares Drop 11% After Wider Quarterly Loss

Before the market opened, Iambic reported a third-quarter loss of $38.5 million, or $8.52 a share, compared with a loss of $21.5 million, or $5.24 a share, a year earlier. Total operating expenses rose 52% to $41.5 million, reflecting higher research and development costs and increased general and administrative expenses.

The quarter also included a $10.4 million non-cash charge related to a change in the fair value of convertible notes. Iambic said the notes converted into common stock immediately before the closing of its initial public offering.

Collaboration revenue more than doubled to $11.4 million, but fell short of the $21 million expected by analysts polled by FactSet.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!